Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: Presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection

Stewart, Meredith; Dovas, Chrysostomos Ι.; Chatzinasiou, E.; Athmaram, T. N.; Papanastassopoulou, Maria; Papadopoulos, O.; Roy, Polly

doi:10.1016/j.vaccine.2012.01.042

Cited by 46 publications

(41 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is accepted that serotype-specific immunity induced by VP2 is required for full protection against BTV infection and is mediated by neutralizing antibody induction (17,18). When it was later evaluated in a subsequent study in cattle, it was shown that the purified recombinant VP2 protein presented herein induced strong BTV-8-neutralizing antibody titers (47).…”

Section: Discussionmentioning

confidence: 93%

“…Experimental vaccines, including disabled infectious single-cycle vaccines, virus-like particles, and subunit vaccines, rely on excluding at least one BTV protein so that detected antibodies against that protein indicate infection rather than vaccination. Thus, they are often protein based using expression systems based on viruses (13)(14)(15)(16)(17)(18), bacteria (19), yeast (20), or plants (21). To aid purification and thus reduce safety and regulatory concerns (22,23), affinity tags can be added to expressed antigens.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Purification, Stability, and Immunogenicity Analyses of Five Bluetongue Virus Proteins for Use in Development of a Subunit Vaccine That Allows Differentiation of Infected from Vaccinated Animals

Anderson

Bréard

Bengtsson

et al. 2014

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

e Bluetongue virus (BTV) causes bluetongue disease, a vector-borne disease of ruminants. The recent northerly spread of BTV serotype 8 in Europe resulted in outbreaks characterized by clinical signs in cattle, including unusual teratogenic effects. Vaccination has been shown to be crucial for controlling the spread of vector-borne diseases such as BTV. With the aim of developing a novel subunit vaccine targeting BTV-8 that allows differentiation of infected from vaccinated animals, five His-tagged recombinant proteins, VP2 and VP5 of BTV-8 and NS1, NS2, and NS3 of BTV-2, were expressed in baculovirus or Escherichia coli expression systems for further study. Optimized purification protocols were determined for VP2, NS1, NS2, and NS3, which remained stable for detection for at least 560 to 610 days of storage at ؉4°C or ؊80°C, and Western blotting using sera from vaccinated or experimentally infected cattle indicated that VP2 and NS2 were recognized by BTV-specific antibodies. To characterize murine immune responses to the four proteins, mice were subcutaneously immunized twice at a 4-week interval with one of three protein combinations plus immunostimulating complex ISCOM-Matrix adjuvant or with ISCOM-Matrix alone (n ‫؍‬ 6 per group). Significantly higher serum IgG antibody titers specific for VP2 and NS2 were detected in immunized mice than were detected in controls. VP2, NS1, and NS2 but not NS3 induced specific lymphocyte proliferative responses upon restimulation of spleen cells from immunized mice. The data suggest that these recombinant purified proteins, VP2, NS1, and NS2, could be an important part of a novel vaccine design against BTV-8.

show abstract

Section: Discussionmentioning

confidence: 93%

mentioning

confidence: 99%

Purification, Stability, and Immunogenicity Analyses of Five Bluetongue Virus Proteins for Use in Development of a Subunit Vaccine That Allows Differentiation of Infected from Vaccinated Animals

Anderson

Bréard

Bengtsson

et al. 2014

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

show abstract

“…Conformation and intracellular location of VLPs is similar to that of BTV, and, therefore, better protection compared to subunit vaccines will likely be induced. Core-like particles of BTV consisting of the inner capsid proteins VP3 and VP7 have been produced by baculovirus expression and were tested as vaccine candidate, but these did not induce protective immunity (Stewart et al, 2012;Thuenemann et al, 2013), likely due to the lack of VP2 expression.…”

Section: Virus-like Particlesmentioning

confidence: 99%

Current and next-generation bluetongue vaccines: Requirements, strategies, and prospects for different field situations

Feenstra

Rijn

2016

Critical Reviews in Microbiology

View full text Add to dashboard Cite

“…VLP have the advantage of being immunogens with the same structural characteristics as the native virus particle but are free of the viral genetic material and cannot therefore pose a risk of transmission (Lua et al, 2014;Roy and Noad, 2008;Stewart et al, 2012;Zhao et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Generation of virus like particles for epizootic hemorrhagic disease virus

Forzan

Maan

Mazzei

et al. 2016

Research in Veterinary Science

View full text Add to dashboard Cite

Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: Presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection

Cited by 46 publications

References 31 publications

Purification, Stability, and Immunogenicity Analyses of Five Bluetongue Virus Proteins for Use in Development of a Subunit Vaccine That Allows Differentiation of Infected from Vaccinated Animals

Purification, Stability, and Immunogenicity Analyses of Five Bluetongue Virus Proteins for Use in Development of a Subunit Vaccine That Allows Differentiation of Infected from Vaccinated Animals

Current and next-generation bluetongue vaccines: Requirements, strategies, and prospects for different field situations

Generation of virus like particles for epizootic hemorrhagic disease virus

Contact Info

Product

Resources

About